Patient-specific dose correction for prostate postimplant evaluation with flexible timing of postimplant imaging

被引:0
|
作者
Luo, Wei [1 ]
Cheek, Denise [1 ]
St Clair, William [1 ]
Washington, Brien [1 ]
机构
[1] Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA
关键词
edema; flexible timing; optimal time; patient-specific dose correction; postimplant CT; COMPUTED-TOMOGRAPHY; SEED IMPLANT; INTERSTITIAL BRACHYTHERAPY; AMERICAN-ASSOCIATION; EDEMA; I-125; DOSIMETRY; RECOMMENDATIONS; PD-103; IMPACT;
D O I
10.1002/mp.15968
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose The dosimetric effect of edema on prostate implants have long been realized, but large uncertainties still exist in the estimation of dose actually received by the prostate. This study attempted to develop a new method to accurately estimate dose delivered to the prostate accounting for the variation of prostate volume and seed distribution, edema half-lives, and times for postimplant evaluation. Methods and materials A series of prostate seed implants for Cs-131, Pd-103, and I-125 with various prostate volumes were simulated in a water phantom using the TG-43 algorithm on the Varian Eclipse treatment planning system. Dose analysis was performed to derive a quantitative relationship between the prostate peripheral dose and the prostate radius with the variation of prostate volume and seed distribution. Using this relationship to calculate dynamically, the total dose accumulated in the prostate (D-T) accounting for the variation of prostate volume and seed distribution and edema half-lives. Moreover, the total dose can be estimated statically based on the prostate volume that can be determined in a computerized tomography (CT) image taken at a time after implantation. The statically estimated total dose (D-CT) was compared with D-T to determine optimal imaging times as well as dose correction factors for other imaging times. Results An inverse power law was established between the prostate peripheral dose and prostate radius. The value of the power was 1.3 for Cs-131 and I-125, and 1.5 for Pd-103, respectively. D-T was derived dynamically using the inverse power law. Given the edema half-lives, T-E, of 4, 9.3, and 25 days and the volume expansion of 1.1 and 2.0 times of the prostate without edema, the optimal times for postimplant imaging were: 7, 9, and 16 days for T-E = 4 days; 10, 14, and 28 days for T-E = 9.3 days; and 12, 19, 45 days T-E = 25 days, for Cs-131, Pd-103, and I-125, respectively. D-CT calculated using the prostate volume determined on the optimal days agreed with D-T to 0.0%-1.8% and within 0.3% for most cases. For various prostate volumes, edema half-lives, and nonoptimal times, D-CT was able to achieve a 1% accuracy. Conclusion The postimplant dose calculation based on the proposed inverse power law for prostate seed implants with edema has improved the accuracy of postimplant dosimetry with accurate and patient-specific dose corrections accounting for prostate size, edema half-life, and postimplant imaging times. Optimal times for postimplant imaging have been accurately determined, and the high accuracy of postimplant dose calculation can be achieved for both optimal imaging times and nonoptimal imaging times.
引用
收藏
页码:6802 / 6812
页数:11
相关论文
共 50 条
  • [21] Influence of dose specification on prostate VMAT patient-specific QA results
    Clemente Gutierrez, F.
    Perez Vara, C.
    Clavo Herranz, M.
    Lopez Carrizosa, C.
    Saez Garrido, J.
    Ibanez Villoslada, C.
    Couselo Paniagua, M.
    Zapatero Ortuno, J.
    Martin de Miguel, M.
    Dominguez Morcillo, M.
    Jerviz Guia, V.
    Calapaqui Teran, A.
    Guijarro Verdu, M.
    Navarro, J.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S726 - S726
  • [22] Correction to: Patient-specific SPECT imaging protocols to standardize image noise
    Sarah G. Cuddy-Walsh
    Duncan C. Clackdoyle
    Jennifer M. Renaud
    R. Glenn Wells
    Journal of Nuclear Cardiology, 2020, 27 : 1382 - 1382
  • [23] Point: The relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: Is there an elephant in the room?
    Morris, W. James
    Halperin, Ross
    Spadinger, Ingrid
    BRACHYTHERAPY, 2010, 9 (04) : 289 - 292
  • [24] Low-dose-rate prostate brachytherapy: 4-8 week postimplant prostate-specific antigen a novel predictor of biochemical failure-free survival
    Callaghan, Cameron M.
    Wang, Lin
    Alluri, Abhishek
    Lauve, Andrew
    Boyer, Cynthia
    Russell, William
    BRACHYTHERAPY, 2017, 16 (06) : 1119 - 1128
  • [25] Comments on "Low-dose-rate prostate brachytherapy: 4-8 week postimplant prostate-specific antigen a novel predictor of biochemical failure-free survival"
    Mansori, Kamyar
    Ayubi, Erfan
    Safiri, Saeid
    BRACHYTHERAPY, 2018, 17 (02) : 514 - 515
  • [26] Postimplant Multiparametric MRI-Based Dosimetry After Permanent Iodine Seed Prostate Brachytherapy: The Impact of the Dose Delivered to the Dominant Intraprostatic Lesion on Prostate-Specific Antigen Bounce
    Quivrin, M.
    Loffroy, R.
    Mirjolet, C.
    Cueff, A.
    Sottier, D.
    Bidault, F.
    Martin, E.
    Maingon, P.
    Walker, P.
    Crehange, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S459 - S460
  • [27] Calculating Patient-Specific Skin Dose
    Pavlicek, W.
    MEDICAL PHYSICS, 2011, 38 (06)
  • [28] Parallel imaging compressed sensing for accelerated imaging and improved signal-to-noise ratio in MRI-based postimplant dosimetry of prostate brachytherapy
    Sanders, Jeremiah W.
    Song, Hao
    Frank, Steven J.
    Bathala, Tharakeswara
    Venkatesan, Aradhana M.
    Anscher, Mitchell
    Tang, Chad
    Bruno, Teresa L.
    Wei, Wei
    Ma, Jingfei
    BRACHYTHERAPY, 2018, 17 (05) : 816 - 824
  • [29] Patient-specific dose from megavoltage CT Imaging with a helical tomotherapy unit
    Shah, A. P.
    Langen, K. M.
    Ruchala, K.
    Cox, A.
    Kupelian, P. A.
    Meeks, S. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S193 - S194
  • [30] Comments on "Low-dose-rate prostate brachytherapy: 4-8 week postimplant prostate-specific antigen a novel predictor of biochemical failure-free survival" Response
    Callaghan, Cameron M.
    BRACHYTHERAPY, 2018, 17 (02) : 515 - 515